<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> is a disorder of the connective tissue that is inherited in an <z:hpo ids='HP_0000006'>autosomal-dominant</z:hpo> fashion and that is caused by mutations in the gene coding for fibrillin-1, FBN1 </plain></SENT>
<SENT sid="1" pm="."><plain>Although complications of the syndrome may involve the eye, the lung and the skeleton, the high mortality of untreated cases results almost exclusively from cardiovascular complications, including <z:hpo ids='HP_0002647'>aortic dissection</z:hpo>, rupture and <z:hpo ids='HP_0001653'>mitral valve regurgitation</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The multiorgan involvement of many of these syndromes requires multidisciplinary expert centers that can increase the average life expectancy of affected patients from only 32 years to over 60 years </plain></SENT>
<SENT sid="3" pm="."><plain>The present article both reviews classical standards of managing cardiovascular manifestations and highlights the surgical approach for aortic and mitral valve surgery in Marfan patients </plain></SENT>
</text></document>